Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
AssigneesInstitut National de la Sante et de la Recherche Medicale, Sorbonne Universite, Université Paris Cité
InventorsOlivier BLANC-BRUDE, Lubka ROUMENINA
Life of this patent
Estimating the term…
Abstract
The inventors generated new mutated Annexin A5 polypeptides to which the binding of heme is drastically reduced, but the binding to phosphatidylserine-bearing membranes remains at the same level in presence of heme or during intravascular hemolysis. Thus mutated polypeptides can therefore be particularly suitable for therapeutic purposes, in order to harness reactions enhanced by PS or PS-bearing membranes, most particularly in pathologies where thrombotic, vaso-occlusive and hemolytic conditions co-exist.
Claims18
A mutated Annexin A5 polypeptide that comprises an amino acid sequence having at least 90% identity with the amino acid sequence as set forth in SEQ ID NO:
- 1 wherein at least one amino acid at position 227, 228 or 257 is mutated.
Dependencies are inferred from the claim text.